• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

    4.005 +0.675 (+20.27%)
    Streaming Delayed Price Updated: 2:59 PM EDT, Jun 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,693,874
    Open 3.510
    Bid (Size) 3.990 (400)
    Ask (Size) 4.020 (500)
    Prev. Close 3.330
    Today's Range 3.440 - 4.190
    52wk Range 1.650 - 6.600
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
    Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D 
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB Biotherapeutics Q1 Earnings Call Highlights ↗
    SAB Biotherapeutics (NASDAQ:SABS) said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a wider... 
    Via MarketBeat
    Topics Earnings

    Performance

    YTD
    +6.2%
    +6.2%
    1 Month
    +8.2%
    +8.2%
    3 Month
    +1.6%
    +1.6%
    6 Month
    +0.1%
    +0.1%
    1 Year
    +135.6%
    +135.6%

    More News

    Read More
    SAB Biotherapeutics (NASDAQ:SABS) Reports Q1 2026 Miss as Clinical Progress and Extended Cash Runway Through 2028 Take Center Stage ↗
    Via Chartmill
    News headline image
    SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO to Participate in Upcoming Investor Conferences
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO to Participate in Upcoming Investor Conferences
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SAB BIO to Participate in Upcoming Investor Conferences
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is SAB Biotherapeutics, Inc. - Common Stock publicly traded?
    Yes, SAB Biotherapeutics, Inc. - Common Stock is publicly traded.
    What exchange does SAB Biotherapeutics, Inc. - Common Stock trade on?
    SAB Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for SAB Biotherapeutics, Inc. - Common Stock?
    The ticker symbol for SAB Biotherapeutics, Inc. - Common Stock is SABS on the Nasdaq Stock Market
    What is the current price of SAB Biotherapeutics, Inc. - Common Stock?
    The current price of SAB Biotherapeutics, Inc. - Common Stock is 4.005
    When was SAB Biotherapeutics, Inc. - Common Stock last traded?
    The last trade of SAB Biotherapeutics, Inc. - Common Stock was at 06/15/26 02:59 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.